RESUMO
The combination creams, betamethasone dipropionate/clotrimazole/gentamicin sulphate and flumethasone pivalate/clioquinol, were compared in patients with corticosteroid responsive dermatoses and/or cutaneous fungal and/or bacterial infections. Medication was applied to affected areas twice daily for 28 days. Of 67 patients enrolled, 31 treated with betamethasone/clotrimazole/gentamicin and 33 given flumethasone pivalate/clioquinol were evaluated for efficacy and safety each week during therapy and once 14 days post-therapy. Disease signs and symptoms were less severe in the group given betamethasone/clotrimazole/gentamicin than in the comparative group at days 7 (P = 0.04), 21 (P = 0.02), 28 (P = 0.09), and 42 (P = 0.09) and at patients' last valid visit (P = 0.06). By the last valid visit, signs/symptoms had improved by 82% for patients treated with betamethasone/clotrimazole/gentamicin versus 68% for those treated with flumethasone pivalate/clioquinol. Patients given betamethasone/clotrimazole/gentamicin had statistically significantly better therapeutic responses than those given flumethasone pivalate/clioquinol at day 7 and, by the last valid visit, 19/31 (61%) patients given betamethasone/clotrimazole/gentamicin compared to 15/33 (45%) given flumethasone pivalate/clioquinol had a complete cure or an excellent therapeutic response. Median time of onset of relief of erythema and pruritus was approximately 2 days, regardless of treatment. No adverse reactions were reported.
Assuntos
Antibacterianos/uso terapêutico , Anti-Inflamatórios/uso terapêutico , Antifúngicos/uso terapêutico , Dermatopatias/tratamento farmacológico , Administração Tópica , Adolescente , Adulto , Idoso , Betametasona/administração & dosagem , Betametasona/análogos & derivados , Betametasona/uso terapêutico , Ensaios Clínicos como Assunto , Clioquinol/administração & dosagem , Clioquinol/uso terapêutico , Clotrimazol/administração & dosagem , Clotrimazol/uso terapêutico , Dermatomicoses/tratamento farmacológico , Quimioterapia Combinada , Feminino , Flumetasona/administração & dosagem , Flumetasona/análogos & derivados , Flumetasona/uso terapêutico , Gentamicinas/administração & dosagem , Gentamicinas/uso terapêutico , Glucocorticoides , Humanos , Masculino , Pessoa de Meia-Idade , Distribuição Aleatória , Dermatopatias Infecciosas/tratamento farmacológico , Fatores de TempoRESUMO
Double blind study with contralateral comparison, between diflucortolon valerianat, 0.1% and the flumetason pivalat, 0.02% in pomades (ointments). Selection of 52 patients both sexes and variable ages with bilateral dermatological inflamatory lesions and with simetric preference: Psoriasis, "eczema vario" and neurodermatitis. In psoriasis, diflucortolon offered better results: the same occurred in the cases of eczema, and in neurodermatitis. The efficacy was similar. There were no appearances of negative secondary effects because of the used doses and time.